Table 1.

Baseline Characteristics of Patients with Chronic Hepatitis C According to Treatment Response

	Median (25–75 percentiles)
Patient characteristics	Non-SVR (n=20)	SVR (n=26)	Total patient group (n=46)	P value
Age (years)	50.5 (39–59)	35 (28–40)	39.5 (30–52)	0.0012
Sex (n, %)				0.391
Male	6 (30%)	11 (42.3%)	17 (37%)
Female	14 (45%)	15 (57.7%)	29 (63%)
Liver biopsy (ISHAK score)
Fibrosis (n, %)				0.010
Stage 1–3	11 (55%)	23 (88.5%)	34 (73.9%)
Stage 4–6	9 (45%)	3 (11.5%)	12 (26.1%)
Histology activity index (HAI, n, %)				0.364
HAI 0–6	6 (30%)	7 (26.9%)	13 (28.3%)
HAI 7–12	11 (55%)	18 (69.2%)	29 (63%)
HAI 13–18	3 (15%)	1 (3–8%)	4 (8.7%)
HCV RNA (IU/mL) before treatment	727,084 (280,140–1,700,000)	266,045 (93,900–694,000)	354,132 (165,000–1,243,560)	0.036
Body mass index	23.9 (22–25.5)	23.7 (21–24.9)	23.7 (21.9–25)	0.527

HCV, hepatitis C virus; SVR, sustained viral response.